PROMISE II Trial Met Primary Endpoint Therapy Demonstrates 76% Limb Salvage in Patients with Chronic Limb-Threatening Ischemia Who Otherwise Faced Amputation PARIS--(BUSINESS WIRE)--LimFlow SA, a ...

CLEVELAND — Cindy Elford was the first patient at University Hospitals Cleveland Medical Center to have her leg saved by the LimFlow device. We met just after the procedure. Years later, she's still ...

PARIS, July 28, 2021 /PRNewswire/ -- Today, LimFlow SA, the pioneer in developing minimally-invasive technology to treat chronic limb-threatening ischemia (CLTI), announced remarkable health economic ...

Daniel Rose was recently appointed CEO of LimFlow, a Paris-based company that’s developing a therapy to restore lower leg blood flow for people with virtually no circulation. Most of these patients ...

Inari Medical has agreed to acquire LimFlow, maker of a device to treat patients with chronic limb-threatening loss of blood flow, for $250 million in cash plus potential milestone payments, bringing ...

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from ...

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and ...

PARIS--(BUSINESS WIRE)--LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery ...

PARIS & SAN JOSE, Calif.--(BUSINESS WIRE)-- LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of ...

The US Food and Drug Administration (FDA) has approved an endovascular device for patients with chronic limb-threatening ischemia (CLTI) at risk for major amputation who are poor candidates for ...

The first ever LimFlow procedure in the Western United States, was performed at Heart Hospital of New Mexico at Lovelace Medical Center by New Mexico Heart Institute vascular surgeons, Steven Henao ...

New data from the PROMISE III trial show the LimFlow transcatheter deep venous arterialization system achieved over 80% amputation-free survival at six months in 'no-option' chronic limb-threatening ...